{"url_path":"/sec/zbio/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","accession_number":"0001104659-26-059700","cik":"0001953926","ticker":"ZBIO","issuer_name":"Zenas BioPharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1953926/0001104659-26-059700-index.html","primary_entity_key":"0001953926","primary_entity_name":"Zenas BioPharma, Inc."},"word_count":87,"has_tables":true,"body_markdown":"**Item 9.01**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit\nNo.**\n \n**Description**\n\n \n \n \n\n[99.1](tm2614295d1_ex99-1.htm)\n \n[Press release issued by the Company on May 13, 2026](tm2614295d1_ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**ZENAS BIOPHARMA, INC.**\n\n \n \n \n\n \nBy:\n/s/ Jennifer Fox\n\n \n \nName:\nJennifer Fox\n\n \n \nTitle:\nChief Business Officer and Chief Financial Officer\n\n \n\nDate: May 13, 2026"}